enGene Therapeutics Inc. (ENGN) stock
ENGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends October 31Also trades as ENGNW
$1.72−0.17 (-8.99%)
Close on Nov 17, 2026Market cap $115.27MP/E –Yield 0.00%
enGene Therapeutics cash
Cash and short-term investments held at the end of each period.
enGene Therapeutics's cash was $266.32M at Jul 31, 2026. For fiscal 2025 it was $193.74M, down 18.7% from the year before. The highest annual figure on record is $238.33M in fiscal 2024.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $193.74M | -18.7% |
| FY2024 | Oct 31, 2024 | $238.33M | +192.4% |
| FY2023 | Oct 31, 2023 | $81.52M | +298.9% |
| FY2022 | Oct 31, 2022 | $20.43M | +85.5% |
| FY2021 | Oct 31, 2021 | $11.02M | – |
Quarterly cash
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | Jul 31, 2026 | $266.32M | +31.9% |
| Q2 FY2026CQ1 2026 | Apr 30, 2026 | $258.47M | +18.9% |
| Q1 FY2026CQ4 2025 | Jan 31, 2026 | $275.95M | +29.1% |
| Q4 FY2025CQ3 2025 | Oct 31, 2025 | $193.74M | -18.7% |
| Q3 FY2025CQ2 2025 | Jul 31, 2025 | $201.91M | -21.6% |
| Q2 FY2025CQ1 2025 | Apr 30, 2025 | $217.39M | -17.9% |
| Q1 FY2025CQ4 2024 | Jan 31, 2025 | $213.81M | +149.6% |
| Q4 FY2024CQ3 2024 | Oct 31, 2024 | $238.33M | +192.4% |
| Q3 FY2024CQ2 2024 | Jul 31, 2024 | $257.68M | +1161.0% |
| Q2 FY2024CQ1 2024 | Apr 30, 2024 | $264.81M | +2303.6% |
| Q1 FY2024CQ4 2023 | Jan 31, 2024 | $85.65M | – |
| Q4 FY2023CQ3 2023 | Oct 31, 2023 | $81.52M | – |
| Q4 FY2022CQ3 2022 | Oct 31, 2022 | $20.43M | – |
| Q4 FY2021CQ3 2021 | Oct 31, 2021 | $11.02M | – |
See a number that looks wrong?